Molecular docking notes: Stereochemical refinement of Mitragyna alkaloids — Research Note

Mitragynine ligand binding pose and catalytic pocket contacts within opioid receptor

Background & Structural Objectives

Mitragyna speciosa (kratom) produces atypical indole alkaloids that elicit analgesic properties with markedly lower respiratory depression than classical opioids. However, computational investigations often utilize non-isomeric 2D chemical representations that lack authentic stereocenters.

This note documents our automated docking evaluation across human Delta Opioid Receptor (OPRD1, PDB: 6PT3) and Kappa Opioid Receptor (KOR, PDB: 4DJH), comparing unrefined 2D geometries against PubChem Isomeric SMILES.

Key Methodological Insights

Native Redocking Validation

Co-crystallized native agonists (DPI-287 on 6PT3) and antagonists (JDTic on 4DJH) achieved crystallographic RMSDs of 1.19 Å and 0.41 Å, well within the strict ≤ 2.0 Å validity threshold.

Stereochemical Refinement (PubChem CID 3614)

Transitioning to verified isomeric SMILES with explicit E-alkene geometry and bridgehead chiral centers altered binding postures and resolved key steric clashes.

Conserved Asp3.32 Salt-Bridge Engagement

Isomeric mitragynine formed a direct 3.34 Å contact with catalytic Asp138 on KOR (-7.4 kcal/mol) and 3.37 Å with Asp128 on OPRD1 (-6.5 kcal/mol), mirroring clinical morphinans.

Spiro-oxindole Core Affinity

Rhynchophylline exhibited robust affinity for KOR (-7.9 kcal/mol) with a 3.25 Å salt-bridge distance, indicating synergistic target coverage in whole-plant extracts.

Without isomeric stereocenter curation, molecular docking results risk mischaracterizing essential active site hydrogen-bonding networks.

Opioid Reference Benchmarks

Benchmarking our test alkaloids against seven reference agonists and clinical antagonists established physiological consistency:

Naltrindole (selective DOR antagonist): $-9.5 \text{ kcal/mol}$ (KOR) / $-9.1 \text{ kcal/mol}$ (OPRD1)
Morphine (standard opioid agonist): $-7.8 \text{ kcal/mol}$ (KOR) / $-8.2 \text{ kcal/mol}$ (OPRD1)
Naloxone (standard opioid antagonist): $-7.6 \text{ kcal/mol}$ (KOR) / $-8.5 \text{ kcal/mol}$ (OPRD1)
Mitragynine (isomeric test compound): $-7.4 \text{ kcal/mol}$ (KOR) / $-6.5 \text{ kcal/mol}$ (OPRD1)

These atomic-level coordinates provide structural rationale for why mitragynine acts as an atypical partial agonist with distinct receptor subtype affinities.